NEW YORK ( TheStreet) -- AVANIR Pharmaceuticals (Nasdaq: AVNR) hit a new 52-week low Wednesday as it is currently trading at $1.97, below its previous 52-week low of $1.98 with 1.2 million shares traded as of 3:29 p.m. ET. Average volume has been 1.5 million shares over the past 30 days.

AVANIR has a market cap of $283.1 million and is part of the health care sector and drugs industry. Shares are down 43.6% year to date as of the close of trading on Tuesday.

Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States.

TheStreet Ratings rates AVANIR as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. You can view the full AVANIR Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Develop Biotech 'Buy-Sell' Strategy

Develop Biotech 'Buy-Sell' Strategy

Two Small-Cap Biotechs To Consider

Two Small-Cap Biotechs To Consider

Next Year's Stock Returns: 5% or 15%?

Next Year's Stock Returns: 5% or 15%?

Updating a Small Speculative Play

Updating a Small Speculative Play

Three Large-Cap Growth Stocks

Three Large-Cap Growth Stocks